临床因素对复发性前列腺癌患者18F-Flotufolastat检出率的影响:3期SPOTLIGHT研究的探索性分析
SPOTLIGHT研究探索性分析评估基线PSA、PSA倍增时间和Grade Group对18F-Flotufolastat检出率的影响。389例可评估患者中,总体检出率随PSA升高而增加(<0.2 ng/mL为33%,≥10 ng/mL为100%);PSA<1 ng/mL者68%扫描阳性,27%有盆腔外发现。PSAdt和GG对检出率无明显影响。
要点
- 389例可评估患者中,既往根治性前列腺切除术±放疗者远处病变检出率39%,仅放疗者43%。
- 总体检出率随PSA升高而增加:<0.2 ng/mL为33%,≥10 ng/mL为100%。
- PSA<1 ng/mL患者中68%扫描阳性,27%有盆腔外发现;PSAdt和GG对检出率无明显影响。
核心结论
- 18F-Flotufolastat正电子发射断层显像可在广泛的PSA、PSAdt和International Society of Urologic Pathology GG范围内准确检出复发性前列腺癌病灶,支持其用于广泛复发性前列腺癌患者的临床效用。
研究设计与样本
- SPOTLIGHT(National Clinical Trials 04186845)为3期研究,本报告为其预先设定的探索性终点分析。
- 纳入所有SPOTLIGHT中扫描可评估的患者,评估基线PSA、PSAdt和International Society of Urologic Pathology Grade Group对18F-Flotufolastat检出率的影响,并按既往治疗(根治性前列腺切除术±放疗[RP]或仅放疗[RT])分层。
- 患者接受18F-Flotufolastat(296 MBq IV)后50至70分钟行正电子发射断层显像,扫描由3名盲法中心读者判读,多数判读代表≥2名读者一致。
主要发现
- 共389例男性可评估,中位PSA为1.10 ng/mL。
- 按多数判读,18F-Flotufolastat在既往RP或RT治疗患者中分别检出39%和43%的远处病变。
- 总体检出率随PSA升高而 broadly 增加(<0.2 ng/mL:33%;≥10 ng/mL:100%)。
- PSA<1 ng/mL患者中,68%扫描阳性,27%有盆腔外发现。
- PSAdt数据见于145/389(37%)患者,PSAdt似不影响18F-Flotufolastat检出率(所有PSAdt类别为77%‒90%);既往RP患者中各PSAdt类别检出率为70%至83%,所有RT后患者报告100%检出率。
局限性
- PSAdt数据仅见于145/389(37%)患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: 18F-Flotufolastat (18F-rhPSMA-7.3) is a newly approved prostate-specific membrane antigen targeting radiopharmaceutical for diagnostic imaging of prostate cancer (PCa). SPOTLIGHT (National Clinical Trials 04186845) evaluated 18F-flotufolastat in men with suspected PCa recurrence. Here, we present results of predefined exploratory endpoints from SPOTLIGHT to evaluate the impact of clinical factors on 18F-flotufolastat detection rates (DR). METHODS AND MATERIALS: The impact of baseline prostate-specific antigen (PSA), PSA doubling time (PSAdt), and International Society of Urologic Pathology Grade Group (GG) on 18F-flotufolastat DR was evaluated among all SPOTLIGHT patients with an evaluable scan, with DR stratified according to the patients' prior treatment (radical prostatectomy ± radiation therapy [RP] or radiation therapy only [RT]). The patients underwent positron emission tomography 50 to 70 minutes after receiving 18F-flotufolastat (296 MBq IV), and scans were read by 3 blinded central readers, with the majority read representing agreement between ≥2 readers. RESULTS: In total, 389 men (median PSA: 1.10 ng/mL) were evaluable. By majority read, 18F-flotufolastat identified distant lesions in 39% and 43% of patients treated with prior RP or RT, respectively. The overall DR broadly increased with increasing PSA (<0.2 ng/mL: 33%; ≥10 ng/mL: 100%). Among patients with PSA <1 ng/mL, 68% had positive scans, and 27% had extrapelvic findings. PSAdt was available for 145/389 (37%) patients. PSAdt did not appear to influence 18F-flotufolastat DR (77%-90% across all PSAdt categories). Among patients with prior RP, DR ranged from 70% to 83% across PSAdt categories, and 100% DR was reported for all post-RT patients. In total, 362/389 (93%) patients had baseline GG data. Overall DRs were uniformly high (75%‒95%) across all GG. When stratified by prior treatment, DRs across all GG were 69% to 89% in patients with prior RP and ≥96% in patients with prior RT. CONCLUSIONS: 18F-Flotufolastat-positron emission tomography enabled the accurate detection of recurrent PCa lesions across a wide range of PSA, PSAdt, and International Society of Urologic Pathology GG, thus supporting its clinical utility for a broad range of patients with recurrent PCa.
引用
- Lowentritt BH, Jani AB, Helfand BT, et al. Impact of Clinical Factors on 18F-Flotufolastat Detection Rates in Men With Recurrent Prostate Cancer: Exploratory Analysis of the Phase 3 SPOTLIGHT Study. Adv Radiat Oncol. 2024. PMID: 39104875. doi:10.1016/j.adro.2024.101532
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。